TScan Therapeutics Inc (NASDAQ:TCRX) announced a poster presentation highlighting preliminary data from the Phase 1 umbrella clinical trial evaluating TSC-100 and TSC-101 targeting minor histocompatibility antigens to prevent relapse after hematopoietic cell transplantation in leukemia patients.

The company's Phase 1 study is rapidly enrolling, and TSC-101 is advancing into the second dose level.

It is on track to reach the recommended Phase 2 dose for TSC-100 and TSC-101 and report interim clinical data for the program by the end of 2023.

In the TSC-101 treatment arm, DL1 administered 21 days after transplant showed expansion between 14-21 days after infusion.

Detectable markers of activation and proliferation were observed.

Twenty-one days after treatment and 42 days after transplant, donor chimerism was at 100% (no detectable patient-derived hematopoietic cells)

No dose-limiting toxicities were observed.

In the TSC-100 treatment arm, DL1 administered 28 days after transplant showed that T cell expansion occurred on Day 7 with detectable T cell activation and proliferation markers.

Last week, Amgen Inc (NASDAQ: AMGN) and TScan Therapeutics announced a multi-year collaboration to use TScan's proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in patients with Crohn's disease. 

Price Action: TCRX shares are down 12% at $3.51 on the last check Wednesday.